Solera Holdings Inc. (NYSE:SLH) the leading global provider of software and services to the automobile insurance claims processing industry, announced that it will release its financial results for the third quarter ended March 31, 2011 on Monday, May 9, 2011 after the market closes. A conference call will be hosted by Tony Aquila, Solera’s founder, chairman and CEO, and Renato Giger, Solera’s CFO, at 5:00 p.m. EDT that evening. The conference call will be webcast live in listen-only mode and can be accessed by visiting the Investor Relations section of the Solera website: www.solerainc.com. A webcast replay will be available on the website until midnight on May 23, 2011. A live audiocast will also be accessible to the public by calling (800) 599-9795 or from outside the U.S., (617) 786-2905. When prompted, the following access code is required: 31415058. Callers should dial in approximately 10 minutes before the call begins. For those unable to participate in the live audiocast, a replay will be available until midnight on May 23, 2011. To access the replay, dial (888) 286-8010 or, from outside the U.S., (617) 801-6888, and enter the following access code when prompted: 49522914.
Solera Holdings, Inc. provides software and services to the automobile insurance claims processing industry. The company was founded in 1966 and is headquartered in San Diego, California.
Power3 Medical Products, Inc (PWRME)
Breast cancer is a common cancer among women. It occurs rarely in men and it doesn’t affect kids. But kids might want to learn about it because they know someone who has it or because they want to learn how to check for it when they are older.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
The human body is made of tiny building blocks called cells. Your body creates them, replacing those that die with new ones. Usually, the body creates healthy, normal cells that do just what they’re supposed to do. This includes cells in the breasts, the two rounded areas on the front of the chest.
Breast cancer is a kind of tumor that develops in the cells of a person’s breast. You may think that only women can get breast cancer, but because all people have breast tissue, men can get breast cancer as well though this is very rare. Someone with breast cancer may have cancer cells in just one part of the breast, which might be felt as a lump. The cancer can spread throughout one or both breasts. Sometimes breast cancer spreads to other parts of the body, like the bones, the liver, or elsewhere.
Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of product NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
BC-SeraPro� is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro� test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com
Majestic Gold Corp. (MJS.V)
Technology related uses of gold in industrial applications, including electronics, dentistry, medicine and nanotechnology, account for around 12% of gold demand and the role gold plays in many industrial applications.
Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.
Electronics is the single largest area of gold usage. Gold is the material of choice in many electronic applications, especially telecommunications, information technology and other high performance and safety critical applications. Examine your mobile phone and you will almost certainly see gold plated contacts; gold is also used in completing the electrical connection inside the chips that control the device. A typical mobile device can contain up to 50mg of gold.
Gold coating is used on the contacts of your telephone cable and telephone jack, so that you can remove the cable and use it in various jacks with no compromising of the sound signal. This is because of gold doesn’t tarnish or corrode.
Majestic Gold Corp. is pleased to provide a progress update on the new mill construction for the company’s flagship Song Jiagou project.
The mill is in the commissioning stage and has begun running ore through the mill in order to access the efficiency of the mill. Majestic expects to run at an initial throughput rate of 3,000 tonnes per day and progressively move upwards towards full capacity of 6,000 tonnes per day once the mill is running at optimal efficiency.
Ore that has been stockpiled at the new mill in order to streamline the commissioning process is currently being processed as part of the commissioning stage. In addition, Majestic is pleased to announce that the tailings dam is fully completed and all tailings lines and water return systems are in place and now in use.
They are excited by the prospect of getting the new mill on line and being in a position to significantly increase production levels. This represents a significant milestone in their transition from exploration to production.
For more information about Majestic Gold Corp. visit its website: http://www.majesticgold.net
Vitamin Shoppe, Inc. (NYSE:VSI) announced preliminary results for its fiscal first quarter ended March 26, 2011. During the period the company reported diluted earnings per share (EPS) of $0.40, up from $0.31 in the comparable period of the prior year. When adjusting for a one-time cumulative charge of $3.7 million ($2.3 million, after tax) for certain non-income-based taxes, EPS was $0.47, a 51.6% increase over the prior year. Comparable store sales increased 8.1%, revenue advanced 13.2% while operating income and net income including the one-time charge rose 15.2% and 32.8%, respectively. After adjusting for the one-time charge, operating income and net income increased 35.8% and 59.1%, respectively.
Vitamin Shoppe, Inc., through its subsidiaries, operates as a specialty retailer and direct marketer of nutritional products. Vitamin Shoppe, Inc. was founded in 1977 and is headquartered in North Bergen, New Jersey.
Duff & Phelps Corporation (NYSE:DUF) announced its first quarter 2011 financial results and declared a quarterly dividend. For the quarter ended March 31, 2011, revenues excluding reimbursable expenses decreased $4.2 million or 4.6% to $85.0 million, compared to $89.2 million for the corresponding prior year quarter. Adjusted EBITDA(1) for the quarter was $12.8 million, representing 15.0% of revenues excluding reimbursable expenses, compared to $15.5 million for the corresponding prior year quarter, representing 17.4% of revenues excluding reimbursable expenses. Net income attributable to Duff & Phelps Corporation was $4.1 million, or $0.14 per share of Class A common stock on a fully diluted basis, compared to $4.3 million, or $0.16 per share for the corresponding prior year quarter. Adjusted Pro Forma Net Income(1) was $6.1 million, or $0.16 per share on a fully exchanged, fully diluted basis, compared to $7.3 million, or $0.19 per share, for the corresponding prior year quarter.
Duff & Phelps Corporation, through its subsidiaries, provides independent financial advisory and investment banking services worldwide. It operates in three segments: Financial Advisory, Corporate Finance Consulting, and Investment Banking.
No comments:
Post a Comment